A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

StatusRecruiting
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: Novo Nordisk A/S to Novo Nordisk A/S
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 9 of 25 entries
    • Site details revised at 179 of 303 sites
  2. Site details revised at 210 of 303 sitesv5
  3. Site details revised at 26 of 303 sitesv4
  4. Study sites revised (303)v3
  5. Recruitment opened
    • Study sites: 302 to 303
    v2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novo Nordisk
269 trials monitored
See 14 trials at risk
Diabetes
5,133 trials monitored
See 238 trials at risk
Obesity
3,903 trials monitored
See 160 trials at risk
Type 2 Diabetes
2,254 trials monitored
See 117 trials at risk
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks
Trial Details
NCT Number NCT07564414
Lead Sponsor Novo Nordisk A/S
Conditions
(from sponsor)		 Obesity, Type 2 Diabetes
Related terms Diabetes Mellitus, Type 2, Obesity
Enrollment 2,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov